Background: Recombinant Fab fragments are attractive as reagents for novel sandwich immunoassays, but no such assays have been described. We developed a duallabel two-site immunoassay based entirely on recombinant Fab fragments and compared it to the same assay with intact monoclonal antibodies. Methods: The capture Fab fragment, which binds free prostate-specific antigen (PSA) and PSA in complex with ␣ 1 -antichymotrypsin on an equimolar basis, is site-specifically biotinylated and attached to the solid phase in streptavidin-coated microtitration wells. The Fab fragment that detects only free PSA is site-specifically labeled with a fluorescent europium chelate, and the Fab fragment that detects both free and serpincomplexed PSA in an equimolar fashion is labeled with a fluorescent terbium chelate. Time-resolved fluorescence is used to measure both europium and terbium signals in one well. Results: The detection limits of the assay (mean ؉ 3 SD of zero calibrator) were 0.043 and 0.28 g/L, respectively, for free and total PSA. The within-run and day-to-day CVs were 2-11% and 4 -10%, respectively. Mean recoveries were 93% and 98% in female and male sera, respectively. Compared with the commercial ProStatus PSA Free/Total Assay, the intercepts of the regression equations (r >0.99) were not significantly different from zero, and the slopes were 0.95-1.01. In one female serum The recent progress within the field of immunodiag-utu.fi.
sample, PSA was falsely increased with the monoclonal assay but was undetectable with the recombinant assay. Conclusions: The performance of this novel assay based on recombinant components is comparable to a conventional assay based on monoclonal antibodies. The more complete control of the essential characteristics of sitespecifically derivatized recombinant Fab fragments will be valuable for the design of miniaturized and multianalyte assay concepts where correct antibody orientation, density, and capacity as well as uncompromised binding affinity are required.
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Monoclonal antibodies have been used in immunoassays since the beginning of the 1980s. Lately, antibody fragments such as Fab and single-chain Fv fragments expressed in Escherichia coli have become potential substitutes for the polyclonal sera and monoclonal antibodies used in research and therapy (1 ) . These recombinant fragments have several potential advantages that can make them valuable tools for future diagnostic concepts. The production of recombinant antibody fragments is less time-consuming and less expensive than the production of polyclonal sera and monoclonal antibodies. Because antibody fragments have been produced as soluble, correctly processed, and active proteins in E. coli in titers of grams per liter (2, 3 ) , the reagent requirements of the diagnostic industry can be easily satisfied. In addition, antibody fragments with different binding specificities can be isolated from large naïve phage display libraries, thus bypassing immunization of animals (4 ) . Recombinant antibody fragments can also be derived by cloning from hybridoma cultures (5 ) . The antigen recognition can be improved in vitro by site-directed or random mutagenesis (6, 7 ) . Peptide tails and amino acid modifications can be introduced by genetic engineering to simplify the purification and labeling of recombinant proteins (8 -10 ) . nostics toward miniaturized assay systems calls for carefully controlled properties of the antibodies used. The simple, passive, and random immobilization of antibodies to plastic surfaces, although successfully used in most of today's immunoassay systems, is highly inefficient because only a minor fraction of the antibodies remains fully functional (11 ) . Especially in cases where the surface area is limited, efficient immobilization of the antibody molecules in the correct orientation is required. At the same time, the tracer antibody should ideally have a high specific activity without negatively affecting the recognition of the antigen. Because random chemical labeling may easily disturb the antigen binding site (12 ) , more specific and controllable methods for derivatization of antibodies are needed. One approach to solve this problem is the introduction of cysteine residues by genetic engineering of the antibody fragment, which then can be labeled by thiol-specific reagents (10, 13, 14 ) . Immobilization can as well be performed by site-specific biotinylation of the capture antibody [Ref. (13 ) ; and Meretoja et al., manuscript in preparation] and attachment to streptavidin-coated wells. A small albumin-binding domain has also been used for the directed attachment of recombinant antibody fragments to microtiter plates coated with human serum albumin (15 ) .
Anti-animal antibodies, complement, or rheumatoid factors present in the sera of some patients can react with the antibodies used in immunoassays, causing either false-positive or -negative test results [reviewed in (16, 17 ) ]. In two-site assays, human anti-mouse antibodies and rheumatoid factors can react with the capture and detection antibodies, linking them together even in the absence of analyte (18 ) . On the other hand, complement factors reacting with solid-phase antibodies may interfere with antigen binding, causing spuriously decreased values (19 -21 ) . A false-positive or -negative result may lead to unnecessary or harmful further investigations and interventions, which can be psychologically stressful for the patient. In large-scale screening tests, a reduction of false results could also be of considerable financial importance. Recombinant antibodies are produced as fragments (Fab or scFv) lacking the Fc part of the antibody, which is a major source of unwanted interferences.
Our aim was to develop an immunoassay based entirely on recombinant Fab fragments produced in E. coli and to compare this assay with an assay based on monoclonal antibodies produced in hybridoma cell culture as whole IgG molecules. Prostate-specific antigen (PSA) 1 was chosen as a model analyte that provides an additional challenge because it exists both as free PSA (F-PSA) and in complex with ␣ 1 -antichymotrypsin (ACT) (22 ) . The determination of serum PSA concentrations has been proposed as a screening test for prostate cancer (CAP) (23 ) , and the discrimination between benign prostatic hyperplasia and CAP can be improved by determination of the ratio of free to total PSA (24 ) . Another purpose of this study was to investigate the feasibility and potential advantages of using site-specifically derivatized Fab fragments in a dual-label two-site immunoassay. As the target for our study, we selected the antibodies of the commercial ProStatus PSA Free/Total (F/T) assay, which was also used as our reference assay. The detection technology used was that of the ProStatus F/T assay, namely the use of time-resolved fluorometry of lanthanide-based chelates (25 ) .
Materials and Methods recombinant Fab fragments
The recombinant anti-PSA Fab fragments were cloned from the hybridoma cell lines H117, H50, and 5A10 by reverse transcription-PCR. Of these, H117 and H50 recognize both free and complexed PSA, whereas 5A10 recognizes only F-PSA (26 ) . H117, which was used as the capture antibody, was genetically engineered to increase the bacterial expression (Jansén et al., manuscript in preparation) and to insert a free cysteine residue at the C-terminal end of the Fd chain (Meretoja et al., manuscript in preparation). H50 and 5A10 were engineered by PCR to contain a Thr-Ser-Cys-Pro-His 6 tag at the Cterminal end of the Fd-chain, using the forward primer 5Ј-TAC TGG GGC CAA GG-3Ј and the reverse primer 5Ј-ACA TGC GAG CTC TTA ATG GTG ATG GTG ATG GTG AGG ACA ACT AGT ACA ATC CCT-3Ј. The product was digested with BamHI and SacI (SacI site is underlined in the reverse primer) and ligated into the similarly treated vector containing the original sequences. The DNA sequences of the final constructs were verified by sequencing the modified regions. The Fab fragments were produced in E. coli, and a periplasmic extract was prepared and purified with a cation-exchange chromatography column (SP STREAMLINE; Pharmacia Biotech), a Ni-NTA Superflow column (Qiagen), and a HiTrap Protein G column (Pharmacia Biotech; Meretoja et al., manuscript in preparation).
labeling with lanthanide chelates and biotinylation
The europium and terbium chelates used for labeling of the detection antibodies were kindly provided by Wallac Labeling Service (Turku, Finland). Two different chelates were used for labeling: a europium(III) chelate of 2,2Ј,2ЈЈ,2ЈЈЈ-[[4-[4-(iodoacetamido)phenylethynyl]pyridine-2,6diyl]bis(methylenenitrilo)]-tetrakis(acetic acid) (27 ) and the terbium(III) chelate of N 1 -(p-iodoacetamidobenzyl)diethylenetriamine-N 1 ,N 2 ,N 3 ,N 3 -tetraacetic acid (28 ) . Before labeling, the purified Fab fragments were stored at Ϫ20°C in 50 mmol/L Tris-HCl (pH 7.75), 15 mmol/L NaCl, 0.5 g/L NaN 3 supplemented with 1 mmol/L dithiothreitol and 2 mmol/L EDTA. Immediately before labeling, the buffer was changed to 50 mmol/L carbonate buffer, pH 8.3, using a NAP-10 column (Pharmacia Biotech), and the protein was concentrated to ϳ1 g/L using a Centricon-10 concentrator (Amicon).
The labeling of Fab fragments was performed with a 30-fold molar excess of label reagent at 4°C for 4 h. The labeled Fab fragment was separated from excess free label on a Superdex 200 HR 10/30 gel filtration column (Pharmacia Biotech) equilibrated and run with 50 mmol/L Tris-HCl (pH 7.75), 15 mmol/L NaCl, 0.5 g/L NaN 3 at 25 mL/h, and 0.5-mL fractions were collected. The fractions containing labeled protein were pooled, the protein concentration was measured by absorbance, and the degree of labeling was determined using a europium or terbium calibration solution (Wallac). Bovine serum albumin was added to a final concentration of 1 g/L, and the solution was filtered through a 0.22 m pore size filter (Millipore) and stored at 4°C. The capture Fab fragment (0.2 g/L) was biotinylated with 50 mol/L 3-(N-maleimido-propionyl)-biocytin (Sigma) (29 ) as described (Meretoja et al., manuscript in preparation).
commercial immunoassay reagents and equipment
All immunoassays were performed using the DELFIA ® technology (Wallac). The following DELFIA reagents and equipment were used: streptavidin-coated strips, Assay Buffer, Wash Concentrate, Enhancement Solution, Enhancer for Tb and Dy measurement, ProStatus PSA F/T kit, Plate Wash, Plateshake, Plate Dispenser, and a 1234 Research Fluorometer.
assay procedures
The principle of the dual-label assay based on recombinant Fab fragments for measurement of free and total PSA (T-PSA) is shown in Fig. 1 , and it will hereafter be referred to as the "rFab F/T PSA assay". The biotinylated capture Fab was immobilized to the streptavidin-coated wells. After a prewash, 160 ng of biotinylated capture Fab per well was added in Assay Buffer supplemented with 2 nmol/L free d-biotin and incubated for 30 min at room temperature with slow shaking. After the wells were washed four times, 25 L of the calibrators (PSA calibrators from the ProStatus PSA F/T kit) or serum samples in duplicate and 100 ng of each tracer Fab fragment in 100 L of ProStatus PSA Assay Buffer were added. The plate was incubated for 30 min at room temperature with slow shaking. After the wells were washed six times, 200 L of Enhancement Solution was added to each well, the plate was incubated for 30 min at room temperature with slow shaking, and the europium signal was measured with the fluorometer. In the dual-label assay, 50 L of Enhancer for Tb and Dy measurement was then added, the plate was incubated for 5 min, and the terbium signal was measured. The MultiCalc immunoassay program created a spline-fitted calibration curve and calculated the unknown PSA concentrations. The assay used as reference, ProStatus PSA F/T Assay, was performed according to the instructions of the manufacturer.
labeling of psa
PSA purified from seminal plasma (30 ) was labeled with europium using the DELFIA Eu-Labeling kit. Briefly, 0.5 mg of PSA in 50 mmol/L carbonate buffer, pH 9.8, was incubated with a 20-fold molar excess of label reagent in a final volume of 500 L overnight at 4°C. The labeled PSA was purified similarly to the labeled Fab fragments. The labeling degree was 2.8 Eu 3ϩ /PSA molecule.
determination of affinity constants
The affinity of the lanthanide-labeled Fab fragments was determined according to the method of Scatchard (31 ) and as described previously (32 ) . To prewashed H117-coated strips from the ProStatus Kit, 25 L of 40 g/L PSA or calibration diluent (0 g/L PSA) was added together with 200 L of six dilutions of labeled Fab (5A10 or H50) between 3.9 and 125 g/L. The strips were incubated for 3 h and then washed, and the fluorescence was measured after development in Enhancement Solution. The affinity of H117 Fab was determined by incubating 200 L of 0 or 5 g/L biotinylated H117 Fab in anti-mouse IgG-coated strips for 2 h, followed by washes. Six dilutions of Eu 3ϩ -labeled PSA (1.5-60 g/L; 200 L) were added and incubated for 2 h; the strips were then washed, and the fluorescence was measured after development in Enhancement Solution. The signals obtained after subtracting the nonspecific binding from the total binding were used to calculate the affinity of the labeled Fab fragment. 
Results

optimization of assay
Labeling degree and amount of antibodies. The labeling degree of the Eu 3ϩ -labeled Fab fragments was 0.7-0.8 Eu 3ϩ / Fab, and that of the Tb 3ϩ -labeled Fab was 0.3 Tb 3ϩ /Fab. The assay optimization (e.g., amount of Fab fragment, and kinetics) and initial serum sample tests were done with both tracer Fab fragments labeled with Eu 3ϩ and assaying the free and total PSA in separate wells. With 160 ng/well of capture Fab, the streptavidin surface was essentially saturated. The optimal amount of both tracer Fabs was 100 ng/well added in ProStatus PSA Assay Buffer. The volume of calibrators and samples was invariably 25 L, and no other sample volumes were tested.
Kinetic experiments. The results from the kinetic experiment showed that a 30-min incubation of sample and tracer Fab at room temperature gave Ͼ90% of the maximum (1 h) signal with concentrations of 2-250 g/L PSA (Fig. 2) . The 30-min incubation time at room temperature was chosen for further assays.
assay characteristics
Calibration curve. A typical calibration curve based on 12 replicates of the calibrators is shown in Fig. 3 . The signal from the Tb 3ϩ -labeled Fab was ϳ10-fold lower than that of the Eu 3ϩ -labeled Fab, as a consequence of both the lower labeling degree (0.3 compared with 0.7) and the lower fluorescence intensity (specific activity) for the terbium chelate. The linear response using the rFab F/T PSA assay extended beyond 1000 g/L for both the free and total PSA assay, even if the highest ProStatus PSA F/T kit calibrator was 250 g/L. Detection limit. The lower limit of detection was defined as the concentration corresponding to a signal 3 SD above the mean of 12 replicates of the zero calibrator (mean values, 200 and 150 cps, respectively, for the free and total PSA assays).
The detection limit of the dual-label assay was 0.043 g/L for F-PSA and 0.280 g/L for T-PSA. When Eu 3ϩ -labeled Fab was used for measurement of T-PSA (single-label assay), the detection limit was 0.070 g/L.
Within-assay variability. The within-assay variability was determined by performing the assay according to the routine protocol both with calibrators (n ϭ 12) and with serum samples (n ϭ 12). The CVs based on calculated concentration for the calibrators were between 15% and 1.5% for F-PSA (F-PSA, 0.09 -249 g/L) and between 22% and 2.6% for T-PSA (T-PSA, 0.51-257 g/L) as shown in Fig. 3 . The CVs for serum samples varied between 1.9% and 11% as shown in Table 1 .
Between-assay variability. The between-assay variability was studied by performing the same assay with calibrators and samples in duplicate for 10 days. The CVs were 4.2-10% for the serum samples. The results are shown in Table 1 .
Analytical recovery. The analytical recovery was studied by adding purified PSA-ACT to male and female serum samples to a final concentration of 10 g/L, and performing the assay to determine the T-PSA concentration in the samples with and without added PSA-ACT. The results are shown in Table 2 . The average recovery of added analyte was 93% in 10 female serum samples and 98% in 9 male serum samples. One male and one female sample gave low recoveries, 68% and 59%, respectively, and the same results were obtained with the ProStatus F/T PSA assay. The recovery test was not performed with F-PSA because free, enzymatically active PSA is captured by serine protease inhibitors, mainly ␣ 2 -macroglobulin, thus escaping immunodetection (21 ) .
Effect of dilution.
To study the effect of dilution, three serum samples with high PSA concentrations were diluted in serum samples with low PSA concentrations, and the results were compared with the calculated results. The measured results correlated well with the calculated results, as shown in Fig. 4 .
affinity constants
The affinity constants of the labeled Fab fragments were 5.3 ϫ 10 9 L/mol for H117 Fab, 4.4 ϫ 10 9 L/mol for 5A10 Fab, and 1.1 ϫ 10 9 L/mol for H50 Fab. The affinity constants of the monoclonal antibodies were 1.0 ϫ 10 10 L/mol for H117, 7.4 ϫ 10 9 L/mol for 5A10, and 1.2 ϫ 10 9 L/mol for H50.
correlation
The correlation between the values obtained by the rFab F/T PSA assay and the ProStatus PSA F/T assay was studied by analyzing 95 serum samples on the same day. The results from both assays were compared and analyzed using linear regression plots (Fig. 5 ). The correlation coefficients were excellent for both the whole PSA range, giving r values of 1.000 for F-PSA and 0.999 for T-PSA, and at PSA concentrations of F-PSA Ͻ1 g/L and T-PSA Ͻ5 g/L, with r values of 0.994 and 0.992, respectively. The y-intercepts were insignificant, and the slopes were between 0.95 and 1.01. One sample from a female, known to give false-positive signals in several different immunoassays regardless of the analyte measured, gave no signal in the rFab F/T PSA assay but gave PSA values of 5.00 and 46.33 g/L for free and total PSA, respectively, in the ProStatus PSA F/T assay. This sample was not included in calculations of linear regression and correlation.
stability
The stabilities of the biotinylated and lanthanide-labeled Fab fragments were studied by storing each Fab fragment (at concentrations between 126 and 243 mg/L) at 4 and 35°C for 1 week, 3 weeks, and 3 months before they were used in the assay. The calibration curves obtained were compared with the calibration curve obtained before the start of the storage experiment. No decrease in activity was observed; even the Fab fragments stored for 3 months at 35°C were indistinguishable from the control. 
Discussion
To our best knowledge, this is the first report of a sandwich-type immunoassay based completely on the use of recombinant Fab fragments. A recombinant ELISA system based on single-chain Fv fusion proteins as coating and detecting reagents has been described previously for the detection of the plant pathogen, beet necrotic yellow vein virus (33 ) . Our assay is a time-resolved immunofluorometric assay that utilizes the DELFIA technology for the simultaneous detection of free and total PSA in one well, using recombinantly produced Fab fragments of the monoclonal antibodies used in the com-mercial ProStatus PSA F/T kit. Three different Fab fragments were used: one for capture, and two for detection of the two measured forms of PSA. All of the Fab fragments were site-specifically modified at a free cysteine residue, which had been introduced by genetic engineering. The capture fragment was biotinylated with a thiol-specific biotinylating reagent, whereas the detection fragments were labeled with iodoacetate derivatives of two different lanthanide chelates. Fab fragments were chosen instead of single-chain antibodies because there have been reports of problems associated with the folding and stability of scFv fragments (34 ) , and because Fab fragments were considered a more reliable alternative when this work was started. In addition, the detection of Fab fragments is easier than that of scFv because anti-mouse antibodies can recognize Fab fragments but not scFv. In the future, it would still be interesting to use scFv for comparison because it may further improve the solid-phase capacity. The rFab F/T PSA assay correlated excellently with the ProStatus PSA F/T Assay, with correlation coefficients Ͼ0.99. However, the lower labeling degree of the Fab fragments compared with the parental intact monoclonal antibodies produced higher limits of detection. The higher detection limit in dual-label assays for T-PSA (0.280 vs 0.043 g/L) is partly attributable to the known lower fluorescence yield of the Tb 3ϩ chelate (35 ) and a lower degree of incorporation of the iodoacetate derivative. The reason for the latter is not known but may have been attributable to decreased reactivity of the thiol group. The single-label assay gave a lower detection limit (0.070 g/L) for T-PSA with an Eu 3ϩ -labeled Fab fragment. The detection limits of the ProStatus PSA F/T assay are reported to be better than 0.04 and 0.10 g/L for F-PSA and T-PSA, respectively, based on a detection limit of 2 SD above the mean value for the zero calibrator (ProStatus PSA F/T kit performance data). Despite the higher detection limits compared with some ultrasensitive assays, the present dual-label assay would be adequate for screening of CAP because the clinical cutoff is usually set at 4 g/L T-PSA (36 ) or in some instances as low as 2.5 g/L (37 ) . However, the assay could not be used for monitoring of CAP patients for relapse after radical prostatectomy because the detection limit required in these cases is at least 0.1 g/L (38, 39 ) , but this is predominantly a consequence of the chelate used.
The expressed aim of the present study was to sitespecifically derivatize the Fab fragments with biotin or lanthanide chelate in a 1:1 manner. This naturally presents a limitation in pursuing lower detection limits. This problem can be solved, however, by the development of branched structures of low molecular weight for introducing several label molecules (40 ) . An alternative approach has been reported with streptavidin coupled to a labeled high-molecular weight protein to improve assay sensitivity (41 ) . Another alternative could be the introduction of additional cysteine residues.
Immunoassays using recombinant antibody fragments, such as the present assay, might overcome some problems inherent in assays based on intact polyclonal or monoclonal antibodies. Unwanted reactions caused by human anti-mouse antibodies, complement, or rheumatoid factors may give rise to false-positive or -negative signals. Although such samples may not be very frequent, they can require substantial additional testing and cause psy-chological stress for the patient. Moreover, they introduce a certain element of uncertainty into the interpretation of all results generated with assays prone to these interferences. In this study, one female sample, known to give false-positive signals in several other two-site assays, gave an expected nondetectable value in the assay based on Fab fragments. Despite the inclusion of a large excess of neutralizing mouse antibodies into the assay buffer, the ProStatus PSA F/T assay based on monoclonal antibodies gave highly increased concentrations of both free and total PSA. Although high PSA concentrations have been reported previously in some female sera (42 ) , the data we have for this sample indisputably show that it causes a false signal in immunoassays based on intact mouse immunoglobulins. Because the only difference between the assays is the absence or presence of the Fc part, the interfering factor is probably either human anti-mouse antibodies or rheumatoid factor that cross-link(s) the capture and detector by reacting with the Fc part of the intact antibody. The Fc part of the antibody molecule is generally known to cause nonspecific interactions, and the interference has been eliminated or substantially reduced by the use of proteolytic Fab or F(abЈ) 2 fragmentation (43, 44 ) . Proteolytic fragmentation of whole IgG molecules is not always straightforward and can be a tedious procedure compared with recombinant techniques, which directly provide a constant source of antibody fragments. Another approach to reduce interference was to use human/mouse chimeric antibodies, which was more effective in reducing interference than the addition of neutralizing mouse antibodies (45 ) .
The low recovery seen with two serum samples is conceivably a result of the presence of autoantibodies to PSA present in these sera. Patients with benign prostatic hyperplasia have been reported to have autoantibodies to PSA (46 ) , and women also could develop antibodies against PSA. Because the ProStatus PSA F/T assay with the same antibody-binding specificities gave equally low recoveries of PSA-ACT in these sera, this cannot be regarded as a problem introduced by the Fab fragments.
Because the Fab fragment accounts for only one-third of the IgG molecule, the coating of wells can be more efficient, and the site-specific biotinylation ensures that the fragments are in the correct orientation and able to bind antigen. This can be a great advantage in the future because the trend in immunodiagnostics is going toward miniaturized assay systems. A more dense capture antibody surface would be especially advantageous in situations where the signal is measured directly from the surface (47 ) compared with situations where the measurement is performed through a separate development step that integrates the signal from larger area into a homogeneous liquid phase. Such situations would be encountered in multianalyte assays where the different analytes are spatially separated on the solid-phase carrier (48 ) . In the present study, we used microtiter wells passively coated with streptavidin to bind the biotinylated Fab fragments, and it is conceivable that the capacity of the immobilized streptavidin is the limiting factor for obtaining a denser antibody surface. Preliminary results indicate that the binding capacity for the anti-PSA Fab fragment can be increased severalfold compared with the intact monoclonal antibody by the use of high-capacity streptavidin surfaces (unpublished observations).
The small size of the Fab fragment may potentially give faster kinetics compared with the whole IgG molecule. Such an advantage would partly stem from the higher, more dense solid-phase capacity and the optimal antibody site orientation after the site-specific derivatization. In part, it would stem from the smaller size of the tracer and its potentially higher degree of access to the epitope on the antigen bound to the capture antibody. Efforts to systematically evaluate the effects of the capture and tracer Fab fragments on the kinetics of the assay were not carried out in this study. A 30-min incubation time was sufficient for the rFab F/T PSA assay, which used a one-step protocol after the immobilization of the biotinylated Fab fragment, compared with the commercial ProStatus PSA F/T kit, which is based on a sequential 1-plus 2-h incubation protocol. However, in a similar PSA assay using monoclonal antibodies, Mitrunen et al. (49 ) reported that maximum signals for both free and complexed PSA were obtained after a 30-min incubation at room temperature. By precoating the streptavidin wells with the capture Fab and storing the dry coated wells, the total assay time and number of steps can be reduced. The concept of the rFab F/T PSA assay is an ideal candidate for applying the all-in-one dry reagent described earlier, providing for an ultimately simplified and rapid assay protocol. Development of such an assay is currently being carried out.
A justified concern was the stability of the recombinant Fab fragments compared with the parental antibodies. This study has shown that the stability of Fab fragments, produced in E. coli and subsequently purified to homogeneity, is as good as that of monoclonal antibodies and, more importantly, that the stability is not affected by the site-specific labeling.
The small size of the Fab fragment compared with the IgG molecule makes it more likely that nonspecific conjugation of the Fab fragments will affect the antigenbinding site (50 ) . The site-specific labeling with biotin and lanthanide chelates of the antibody fragments was fully successful in reducing this risk. We compared the affinities of the three labeled Fab fragments with the labeled monoclonal antibodies to reveal any alteration of the antigen binding. Some minor (twofold or less) differences could be seen, but these are not likely to be of any practical importance; rather they are probably a consequence of the somewhat inaccurate method used for the determination of affinity constants. The approximately twofold decrease in affinity of H117 Fab is presumably attributable to the genetic engineering performed to improve the bacterial expression (Jansén et al., manuscript in preparation).
In conclusion, we have demonstrated that the performance of an assay based entirely on recombinant Fab fragments is at least comparable to that of an assay based on monoclonal antibodies. Recombinant bacterial techniques for the establishment of new immunoreagents and the exact tailor-made modifications of these are likely to overcome some of the problems present in assays that use monoclonal antibodies or polyclonal sera, such as some sample-derived interferences, negative effects from antibody conjugations, inadequate capacities, and slow kinetics. The advantage of the carefully controlled qualities of recombinant antibodies in immunoassays will most probably increase during the years to come. This will especially be the case in the design of future multianalyte diagnostic systems where miniaturization of assays is combined with uncompromised analytical performance.
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